New research suggests there may be a cardiovascular benefit to considering dual antiplatelet therapy for valve-in-valve TAVR patients.

"There is already a deficit of doctors in the U.S., and this will make it worse," one cardiologist told Cardiovascular Business. Medical societies throughout the country seem to agree. 

The document provides an in-depth look at the close relationship between inflammation and cardiovascular disease. "The time for taking action has now arrived," the authors wrote. 

Healthcare's cost-conscious environment prompted the ACC and AHA to develop a statement on the value methodology to be used when creating clinical practice guidelines.

Martha Gulati, MD, co-chair on a new joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology, discusses the dire need she sees to boost prevention efforts for heart failure.

Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

Cardiovascular disease remains the world’s leading cause of death, according to a special report from the American College of Cardiology. The new analysis, described by one cardiologist as a "wake-up call," includes data from more than 200 countries and territories.

There have been so many developments in the treatment of TR that it can be challenging to keep up. The ACC crafted this new document to help ensure cardiologists, cardiac imagers and other clinicians have access to the most recent clinical data and policy decisions.